Latest News
Daraxonrasib FDA Approval Sets a New Bar in Pancreatic Cancer
The daraxonrasib FDA approval, granted on 26 August 2026, gives metastatic pancreatic cancer its first approved targeted therapy. Revolution Medicines will sell the drug as Rasonque. The agency cleared it roughly six and a half months ahead of its goal date. For an...
Latest News
Weekly News Roundup | 24 August 2026
Life science news 24 August 2026: the FDA clears Regeneron’s Pasatru for an ultra-rare bone disorder and grants Ultragenyx the first gene therapy for glycogen storage disease type Ia, authorises the first standalone robotic blood-draw device, and the MHRA opens a...
The Role of Ambient AI in the Future of Specialty Care
For over a decade, the administrative burden in specialty medicine has quietly worsened. Orthopedic surgeons doing 40 patients a day are spending more time in the EHR than in the room. Ambient AI scribes have changed that equation in ways that are only beginning to...
Intismeran Autogene Phase 3 Win Moves Cancer Vaccines to Logistics
Merck and Moderna have reported what they describe as the first positive Phase 3 result for an individualised cancer therapy. Intismeran autogene, given with pembrolizumab, met its primary endpoint in resected melanoma. The companies announced the outcome on 19 August...
APAC Biopharma in 2026: Asia’s Shift From Supplier to Source
APAC biopharma has stopped being a cost line in somebody else’s budget. For two decades the region supplied ingredients, capacity and inexpensive trial sites. The companies that used them were headquartered elsewhere. That relationship has now inverted. The clearest...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Bridging Cosmetic Science & Clinical Research: When Beauty Becomes Therapeutic
The evolving landscape of cosmetic science is increasingly defined by its convergence with clinical research, challenging long-standing distinctions between aesthetic enhancement and therapeutic intervention. Historically, cosmetics have been confined to products...
Asia Is No Longer Pharma’s Factory. It Is Becoming the Source
Two deals announced within days of each other this month read, on their own, like routine deal flow news. South Korea’s Alteogen signed its seventh platform licensing agreement with a global pharmaceutical company. Fujifilm and Taiho Pharmaceutical agreed to build...
Catching Pediatric Strabismus: When It Is More Than a Glare Reaction
Monocular eye closure in bright sunlight glare can often be interpreted as a benign photic response in pediatric patients. However, the behavior may point to an early or intermittent manifestation of binocular vision dysfunction such as intermittent exotropia....
Regulation Is Pushing European Medtechs to Streamline Clinical Trials
Europe’s changing macroeconomic and regulatory environment is prompting the medtech industry to rethink clinical processes and technologies. New insights reveal focus on establishing a unified digital foundation as medtech companies look to optimise data strategy,...
Treating Antimicrobial Resistance as a Healthcare Infrastructure Priority
Modern healthcare depends on a basic assumption: when infections occur, clinicians will have medicines that can treat them. But antimicrobial resistance (AMR) is beginning to challenge that assumption at a systems level. For many years, AMR has been discussed...
Weekly News Roundup | 10 August 2026
Life science news 10 August 2026: Curium pays up to $8 billion for Lantheus to build a radiopharma giant, AstraZeneca’s shares slide on reported $400 billion Bristol Myers Squibb talks, and the MHRA approves a first-in-class BTK inhibitor for chronic hives in an...
Beyond Cytotoxic Payloads: The Expansion of Non-traditional Conjugates
For over two decades, the narrative surrounding targeted biologics has been dominated by antibody-drug conjugates (ADCs) armed with cytotoxic small molecules designed to destroy cancer cells. While oncology remains a primary target for biologics, the therapeutic...
The Public Paper Trail: What Commercial Teams Find Out Last
For most of a decade, I worked on the commercial side of life sciences, and the same thing kept happening. Something would change at an account. A financing would close, a trial would move into a new phase, or a facility would receive an inspection observation. I...
Clinical Trials Roundup | 07 Aug 2026
Merck’s tulisokibart meets its primary and key secondary endpoints in a Phase 2 hidradenitis suppurativa study but misses in systemic sclerosis-associated interstitial lung disease, Eli Lilly’s olomorasib receives a second FDA Breakthrough Therapy designation in KRAS...
Why AI Pilots Fail in Life Sciences
Misaligned incentives, the wrong unit of work, and a probabilistic model where the process demands a reproducible one A draft annex to European GMP guidance, out for consultation until October 2025, contains the bluntest sentence yet written about AI in regulated...
Prevention by Design: How Korea’s Health System Diverges from America’s
South Korea and the United States are both wealthy, technologically sophisticated countries with excellent physicians and world-class hospitals. Yet they placed opposite structural bets on what a health system is for. America bet on treating disease as well as it can...
New Approach Methodologies: What Regulators Now Accept
New approach methodologies have moved from the margins of preclinical science to the centre of regulatory policy. Since publishing its Roadmap to Reducing Animal Testing in Preclinical Safety Studies in April 2025, the United States Food and Drug Administration has...
Bridging Cosmetic Science & Clinical Research: When Beauty Becomes Therapeutic
The evolving landscape of cosmetic science is increasingly defined by its convergence with clinical research, challenging long-standing distinctions between aesthetic enhancement and therapeutic intervention. Historically, cosmetics have been confined to products...
Asia Is No Longer Pharma’s Factory. It Is Becoming the Source
Two deals announced within days of each other this month read, on their own, like routine deal flow news. South Korea’s Alteogen signed its seventh platform licensing agreement with a global pharmaceutical company. Fujifilm and Taiho Pharmaceutical agreed to build...
Catching Pediatric Strabismus: When It Is More Than a Glare Reaction
Monocular eye closure in bright sunlight glare can often be interpreted as a benign photic response in pediatric patients. However, the behavior may point to an early or intermittent manifestation of binocular vision dysfunction such as intermittent exotropia....
Regulation Is Pushing European Medtechs to Streamline Clinical Trials
Europe’s changing macroeconomic and regulatory environment is prompting the medtech industry to rethink clinical processes and technologies. New insights reveal focus on establishing a unified digital foundation as medtech companies look to optimise data strategy,...
Treating Antimicrobial Resistance as a Healthcare Infrastructure Priority
Modern healthcare depends on a basic assumption: when infections occur, clinicians will have medicines that can treat them. But antimicrobial resistance (AMR) is beginning to challenge that assumption at a systems level. For many years, AMR has been discussed...
Weekly News Roundup | 10 August 2026
Life science news 10 August 2026: Curium pays up to $8 billion for Lantheus to build a radiopharma giant, AstraZeneca’s shares slide on reported $400 billion Bristol Myers Squibb talks, and the MHRA approves a first-in-class BTK inhibitor for chronic hives in an...
Beyond Cytotoxic Payloads: The Expansion of Non-traditional Conjugates
For over two decades, the narrative surrounding targeted biologics has been dominated by antibody-drug conjugates (ADCs) armed with cytotoxic small molecules designed to destroy cancer cells. While oncology remains a primary target for biologics, the therapeutic...
The Public Paper Trail: What Commercial Teams Find Out Last
For most of a decade, I worked on the commercial side of life sciences, and the same thing kept happening. Something would change at an account. A financing would close, a trial would move into a new phase, or a facility would receive an inspection observation. I...
Clinical Trials Roundup | 07 Aug 2026
Merck’s tulisokibart meets its primary and key secondary endpoints in a Phase 2 hidradenitis suppurativa study but misses in systemic sclerosis-associated interstitial lung disease, Eli Lilly’s olomorasib receives a second FDA Breakthrough Therapy designation in KRAS...
Why AI Pilots Fail in Life Sciences
Misaligned incentives, the wrong unit of work, and a probabilistic model where the process demands a reproducible one A draft annex to European GMP guidance, out for consultation until October 2025, contains the bluntest sentence yet written about AI in regulated...
Prevention by Design: How Korea’s Health System Diverges from America’s
South Korea and the United States are both wealthy, technologically sophisticated countries with excellent physicians and world-class hospitals. Yet they placed opposite structural bets on what a health system is for. America bet on treating disease as well as it can...
New Approach Methodologies: What Regulators Now Accept
New approach methodologies have moved from the margins of preclinical science to the centre of regulatory policy. Since publishing its Roadmap to Reducing Animal Testing in Preclinical Safety Studies in April 2025, the United States Food and Drug Administration has...
Featured Articles
Further News
Evaluating Retrieval Systems for Clinical AI
Clinical decision support is not new, and it does not have to be complex to work. If anything, the simpler it is, the more likely clinicians are to use it. The best-known earlier example is the WHO surgical safety checklist, developed by a team led by Atul Gawande,...
Women-Led Biotech Is Outperforming. Why Is Capital Lagging?
A new therapeutic can take a decade. Often hundreds of millions of dollars. Regulators checking the work at every stage along the way. So when a category of founders consistently delivers better returns on less capital, you'd expect investment patterns to reflect...
CSRD Reporting: What Has Changed for European Biotech
The European Union has rewritten its sustainability disclosure rules. The consequences for the life sciences sector are substantial. CSRD reporting was once expected to capture tens of thousands of companies across the bloc. It now applies to a far smaller group of...
Microalgae Biomaterials: Where the Carbon Math Holds, and Where it Fails
A research team at the University of Colorado Boulder took a marine dinoflagellate called Pyrocystis lunula, mixed it into 4 wt% sodium alginate, crosslinked the gel ionically in calcium chloride, and extruded it through a Cellink BIO X bioprinter into printed grids...
NHS Golden Jubilee First Scottish Hospital to Adopt Steriwave
NHS Golden Jubilee Becomes First Scottish Hospital to Adopt Light-Activated Infection Prevention Technology to Prevent Surgical Site Infections GLASGOW — Scotland’s flagship orthopaedic hospital, NHS Golden Jubilee, has become the first in the country to adopt an...
Receptor.AI and Sethera Partner on AI-Guided Peptide Drug Discovery
Receptor.AI and Sethera Therapeutics Form Integrated Discovery Alliance for AI-Guided Polymacrocyclic Peptide Medicines Collaboration combines Sethera's proprietary enzymatic polymacrocyclisation and trillion-scale encoded screening with Receptor.AI's physics-based...
Dual and Triple Agonists Explained: GLP-1, GIP and Glucagon
Obesity and diabetes medicine has moved a long way from the single-hormone era. Dual and triple agonists are engineered molecules that switch on two or three hormone receptors at once. They now dominate the late-stage pipeline, and the highest doses tested have...
Ziltivekimab ZEUS Trial: What the Null Result Means
The ziltivekimab ZEUS trial has produced one of the more instructive negative results in recent cardiovascular medicine. Novo Nordisk announced headline results on 31 July 2026 showing that its once-monthly interleukin-6 inhibitor ziltivekimab lowered inflammation...
How the Gut-Brain-Metabolism Axis Is Reshaping Targeted Therapy
For decades, the fields of oncology, neuroscience, and microbiology operated in distinct silos within therapeutic research and clinical practice. Modern drug discovery, however, is rapidly witnessing a paradigm shift toward systemic biology. Researchers increasingly...
Singapore Radiopharmaceutical Market: How H2 2026 Looks
The Singapore radiopharmaceutical market enters the second half of 2026 with more clinical capacity, more research output and a heavier regulatory calendar than at any previous point. New imaging infrastructure came online at the end of 2025, first-in-human data from...
Why True Health Foods Need Evidence, Not Fashion
Functional foods have entered the mainstream, but adding a recognised ingredient is not the same as creating a credible product. A cardiologist argues that the category’s next phase will be won on scientific rationale, dose and honest communication, not on the length...
How Clinical Research Is Transforming the Future of Sarcoma Care
Rare cancers present one of the greatest challenges in modern oncology. Individually uncommon but collectively accounting for around one in five cancer diagnoses worldwide, they have historically attracted less research funding, fewer clinical trials and limited...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.